Optimizing levofloxacin delivery using nanoparticles: a strategy for improved bioavailability and targeted release
Abstract
Nanoparticle-based drug delivery systems have emerged as a powerful strategy to enhance drug bioavailability and ensure targeted therapeutic release. Levofloxacin (LFX), a widely used broad-spectrum fluoroquinolone antibiotic, is limited by poor aqueous solubility, low oral bioavailability, and systemic side effects. This study investigates the formulation, characterization, and evaluation of levofloxacin-loaded nanoparticles aimed at improving its pharmacological performance. Various nanoparticle carriers, including polymeric nanoparticles, lipid-based nanocarriers, and inorganic nanoparticles, were explored for their ability to encapsulate LFX and improve its delivery. Key formulation parameters such as encapsulation efficiency, drug loading, in vitro release profile, and stability at 4°C, 25°C, and 40°C were assessed. The optimized formulations demonstrated acceptable stability and sustained drug release across the tested conditions. Biocompatibility studies revealed no significant cytotoxic effects, as confirmed by high cell viability percentages, indicating the safety of the nanoparticle systems. Furthermore, the nanoparticle-loaded formulations exhibited enhanced dissolution behavior and potent in vitro antimicrobial activity against both Gram-negative and Gram-positive bacteria (p<0.05). Pharmacokinetic studies revealed statistically significant improvements (p<0.05) in maximum plasma concentration (Cmax), elimination half-life (t1/2), and area under the curve (AUC) compared to conventional formulations. In vivo evaluation using an infection model confirmed the superior antimicrobial efficacy of the nanoparticle-based system. The results collectively indicate that nanoparticle-based delivery of LFX substantially improves its bioavailability, pharmacokinetic profile, and therapeutic efficacy. These findings support the potential application of nanotechnology in overcoming the limitations of conventional LFX therapy and enhancing clinical outcomes in bacterial infection treatment.
Keywords: Nanoparticle, Levofloxacin, Bioavailability, Encapsulation efficiency, Drug release kinetics
Keywords:
Nanoparticle, Levofloxacin, Bioavailability, Encapsulation efficiency, Drug release kineticsDOI
https://doi.org/10.22270/jddt.v15i5.7119References
1. Fox GJ, Nhung NV, Binh NC, Hoa NB, Garden FL, Berodetti A, Yen PN, Marks GB. New England Journal of Medicine, 2024; 391: 2304-2314. https://doi.org/10.1056/NEJMoa2314325
2. Zusso M, Lunardi V, franceschini D, Pagetta A, Lo R, Stifani S. Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway. Journal of Neuroinflammation, 2019; 16(1): 148. https://doi.org/10.1186/s12974-019-1538-9 PMid:31319868 PMCid:PMC6637517
3. Bush LM, Chaparro-Rojas F, Okeh V, Etienne J. Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy. Infection and Drug Resistance, 2011; 4: 177-89 https://doi.org/10.2147/IDR.S15610 PMid:22114510 PMCid:PMC3215342
4. Patel R, Kumar A, Mehta P. Advances in nanoparticle-based antibiotics: Enhancing bioavailability and targeting bacterial infections. Nanomedicine. 2022; 18(5):215-230.Singh P, Sharma K. Polymeric nanoparticles in antibiotic delivery: A pathway to enhanced efficacy and reduced resistance. International Journal of Pharmaceutical Science and Research, 2023; 45(3):112-128.
5. Mukhopadhyay S, narayan R, Gadag S, Shenoy PA, garg S, Ashwini T, Nayak UY. Development of levofloxacin glycosylated mesoporous silica nanoparticles for urinary tract infections. Journal of Applied Pharmaceutical Science, 2024; 14(12): https://doi.org/10.7324/JAPS.2024.181547
6. Chen H, Zhang W, Liu X. Controlled release systems for antibiotics: Enhancing treatment efficacy and patient compliance. Pharmaceutics, 2022; 14(7):1452.
7. Kumar S, Bose R, Roy P. pH-sensitive drug delivery systems for bacterial infections: Recent progress and challenges. Drug Delivery Transl Res. 2023; 13(2):320-336.
8. Gupta R, Verma S. Intracellular drug delivery of fluoroquinolones using nanoparticle-based systems: An emerging approach against tuberculosis. European Journal of Pharmacy and Biopharmaceutics, 2021;166:183-194.
9. Mitra A, Singh V, Pandey P. Chitosan-based nanoparticles for antibacterial therapy: A promising alternative to conventional antibiotics. Carbohydrate Polymers, 2024;280:119042.
10. Hassan M, Younis T, Salem R. Strategies to combat antibiotic resistance using nano-antibiotics. Journal of Nanobiotechnology, 2022;20(1):185.
11. Imam SS, Bukhari SN, Ahmad J, Ali A. Advances in polymeric and non-polymeric nanocarriers for the magnified delivery of levofloxacin against bacterial infection. Journal of Nanoparticle Research, 2024;26(3):87. https://doi.org/10.1007/s11051-024-06087-z
12. Francesca A. Nanoparticle-based drug delivery systems: impact on bioavailability and therapeutic efficacy. Journal of Formulation Science and Bioavailability, 2024;8(3):213.
13. Patra JK, Das G, Fraceto LF, Campos EV, Rodriguez-Torres MP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Bromelain-capped gold nanoparticles as the novel drug delivery carriers to aggrandize effect of the antibiotic levofloxacin. Cellular and Molecular Biology (Noisy-le-grand). 2025;63(2):108-114.
14. Gaspar MC, Blanco D, Cruz ME, Alonso MJ. Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery: design and characterization. European Journal of Pharmacy and Biopharmaceutics, 2025;108:65-75.
15. Imam SS, Bukhari SN, Ahmad J, Ali A. Formulation and optimization of levofloxacin loaded chitosan nanoparticle for ocular delivery: in-vitro characterization, ocular tolerance and antibacterial activity. International Journal of Biological Macromolecule, 2018;108:650-659. https://doi.org/10.1016/j.ijbiomac.2017.11.170
16. Cheow WS, Hadinoto K. Enhancing encapsulation efficiency of highly water-soluble antibiotic in poly(lactic-co-glycolic acid) nanoparticles: modifications of standard nanoparticle preparation methods. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2010;370(1-3):79-86. https://doi.org/10.1016/j.colsurfa.2010.08.050
17. Derbali RM, Aouadi C, Moussa G, Elaissari A, Fessi H, Charcosset C. Tailored nanocarriers for the pulmonary delivery of levofloxacin against Pseudomonas aeruginosa: a comparative study. Molecular Pharmaceutics, 2019;16(5):1906-1916. https://doi.org/10.1021/acs.molpharmaceut.8b01256 PMid:30900903
18. Gevariya HB, Gami S, Patel N. Formulation and characterization of levofloxacin-loaded biodegradable nanoparticles. Asian Journal of Pharmacy, 2011; 5(2):114-119. https://doi.org/10.4103/0973-8398.84552
19. Alves DA, Lima MV, Lima EM, Oliveira AG, Ferreira D, Nunan EA. Preparation of thermosensitive gel for controlled release of levofloxacin and their application in the treatment of multidrug-resistant bacteria. Biomedical Research International, 2016;2016:9702129. https://doi.org/10.1155/2016/9702129 PMid:27689094 PMCid:PMC5027370
20. Gaspar MC, Blanco D, Cruz ME, Alonso MJ. Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy. European Journal of Pharmaceutics and Biopharmaceutics, 2015;96:65-75. https://doi.org/10.1016/j.ejpb.2015.07.010
21. Siafaka P, Okur ME, Ayla Ş, Er S, Cağlar EŞ, Okur NÜ. Design and characterization of nanocarriers loaded with levofloxacin for enhanced antimicrobial activity; physicochemical properties, in vitro release and oral acute toxicity. Brazillian Journal of Pharmacutocal Sciences, 2019;55:e18295. https://doi.org/10.1590/s2175-97902019000118295
22. Fatahi Y, Dadashpour M, Sheervalilou R, Pilehvar-Soltanahmadi Y, Zarghami N. Levofloxacin-halloysite nanohybrid-loaded fibers based on poly(ethylene oxide) and sodium alginate: fabrication, characterization, and antibacterial property. Journal of Drug Delivery Science and Technology, 2021;64:102598. https://doi.org/10.1016/j.jddst.2021.102598
23. Sangole S, Salave S, Rana D, Shah S, Medhe TP, Benival D. Electrospun nanofiber composite for levofloxacin in ocular drug delivery. Pharmaceutical Nanotechnology, 2022;10(5):362-372. https://doi.org/10.2174/2211738510666220902151906
24. Gupta H, Aqil M, Khar R, Ali A, Bhatnagar A, Mittal G. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. Journal of Drug Targeteting, 2011;19(6):409-417. https://doi.org/10.3109/1061186X.2010.504268
25. Baig MS, Ahad A. Application of Box-Behnken Design for Preparation of Levofloxacin-Loaded Stearic Acid Solid Lipid Nanoparticles for Ocular Delivery: Optimization, In Vitro Release, Ocular Tolerance, and Antibacterial Activity. International Journal of Biological Macromolecules, 2016; 85, 258-270. https://doi.org/10.1016/j.ijbiomac.2015.12.077 PMid:26740466
26. Cheow WS, Hadinoto K. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids and Surfaces B: Biointerfaces, 2011 Jul 1;85(2):214-20. PMID: 21439797. https://doi.org/10.1016/j.colsurfb.2011.02.033
23. Wang Y, Li Z, Chen H. PEGylation strategies for nanoparticle-based drug delivery: Improving circulation and biodistribution. Advanced Drug Delivery and Reviews, 2021;174:122-138.
24. Gao W, Chen Y, Zhang Y, Zhang Q, Zhang L. Nanoparticle-based local antimicrobial drug delivery. Advanced Drug Delivery and Reviews, 2018; 127:46-57. https://doi.org/10.1016/j.addr.2017.09.015 PMid:28939377 PMCid:PMC5860926
25. Zhao F, Liu J, Xu D. Functionalized nanoparticles for targeted antibiotic delivery: Overcoming bacterial resistance. Journal of Control Release, 2024;369:125-140.
26. Zhang X, Zhao Y, Feng J. PLGA nanoparticles for antibiotic delivery: Overcoming challenges and future perspectives. Molecular Pharmaceutics, 2023;20(2):135-150.
27. Almawash S. Solid lipid nanoparticles: An effective carrier for classical antifungal drugs. Saudi Pharmaceutical Journal,2023; 31(7), 1167-1180. https://doi.org/10.1016/j.jsps.2023.05.011 PMCid:PMC10236373
Published
Abstract Display: 459 
PDF Downloads: 496 PDF Downloads: 49 How to Cite
Issue
Section
Copyright (c) 2025 Chukwuemeka Emmanuel Ogba, Akpabio Elijah Akwaowoh , Ifeoluwa Adetomiwa Taiwo , Precious Joshua Edem , Sunday Olajide Awofisayo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.